Companies
Cyprotex
the in-vitro ADMET and high-content-toxicology leader (Macclesfield, UK), now within Labcorp — its devTOX quickPredict human-iPSC developmental-toxicity assay and miniaturised 96-well CYP induction workflows were both presented in 2026,…
- Country
- United Kingdom
Commercial
GLP / OECD
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 1999 | evotec.com |
| Headquarters | United Kingdom | evotec.com |
| Headcount | 136 employees as of December 2016 | evotec.com |
| Production site | Macclesfield and Alderley Park, UK; Watertown, MA and Kalamazoo, MI, USA | evotec.com |
| Regulatory approval | devTOX quickPredict has an FDA-agreed Context of Use statement and complies with ICH S5(R3) definitions | labcorp.com |
Independent sources: evotec.com · labcorp.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Toxics screening (toxicomics, service) | bioinformatics-omics | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.